SandboxAlonso: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pindolol}} | |||
{{CMG}} | {{CMG}} | ||
{{SB}} | '''''For patient information about Pindolol, click [[Pindolol (patient information)|here]].''''' | ||
{{SB}} Visken | |||
==Overview== | ==Overview== | ||
''' | '''Pindolol''' ('''Visken''', '''Betapindol''', '''Blockin L''', '''Blocklin L''', '''Calvisken''', '''Cardilate''', '''Decreten''', '''Durapindol''', '''Glauco-Visken''', '''Pectobloc''', '''Pinbetol''', '''Prindolol''', '''Pynastin''') is a [[beta blocker]]. | ||
==Category== | ==Category== | ||
Beta | Beta blockers | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
==== | ====Visken (pindolol) Tablet==== | ||
''' [[ | ''' [[Pindolol indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Pindolol dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Pindolol contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Pindolol warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Pindolol adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Pindolol drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Pindolol use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[Pindolol overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Pindolol description|Description]]''' | ||
'''| [[ | '''| [[Pindolol clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Pindolol how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[ | '''| [[Pindolol patient counseling information|Patient Counseling Information]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Pindolol is a '''nonselective''' beta blocker with partial beta-adrenergic receptor agonist activity. It possesses '''ISA (Intrinsic Sympathomimetic Activity)'''. This means that pindolol, particularly in high doses, exerts effects like epinephrine or [[isoprenaline]] (increased pulse rate, increased blood pressure, bronchodilation), but these effects are limited. Pindolol also shows membrane stabilizing effects like [[quinidine]], possibly accounting for its antiarrhythmic effects. It also functions as a [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] weak [[partial agonist]] / [[receptor antagonist|antagonist]] (K<sub>i</sub>=33nM<ref>{{cite web|title=PDSP|url=http://pdsp.med.unc.edu/pdsp.php?|accessdate=12 June 2013}}</ref>). | |||
==Pharmacokinetics== | |||
Pindolol is rapidly and well absorbed from the GI tract. It undergoes some first-pass-metabolization leading to an oral bioavailability of 50 to 95%. Patients with uremia may have a reduced bioavailability. Food does not alter the bioavailability, but may increase the resorption. Following an oral single dose of 20 mg peak plasma concentrations are reached within 1 to 2 hours. The effect of pindolol on pulse rate (lowering) is evident after 3 hours. Despite the rather short halflife of 3 to 4 hours, hemodynamic effects persist for 24 hours after administration. Plasma halflives are increased to 3 - 11.5 hours in patients with renal impairment, to 7 – 15 hours in elderly patients, and from 2.5 to 30 hours in patients with liver cirrhosis. Approximately 2/3 of pindolol are metabolized in the liver giving hydroxylates, which are found in the urine as gluconurides and ethereal sulfates. The remaining 1/3 of pindolol is excreted in urine in unchanged form. | |||
==Indications== | |||
* [[Angina pectoris]] and [[hypertension]]. The use of pindolol in the treatment of unstable angina may be less effective compared to beta blockers without ISA. | |||
* In some other countries also [[arrhythmias]] and prophylaxis of acute [[Stress (medicine)|stress]] reactions. | |||
==Investigational Use== | |||
* Augmentation therapy of [[clinical depression]]: Pindolol is sometimes added to a standard antidepressant therapy,<ref name="pmid15504795">{{cite journal |author=Isaac MT |title=Review: combining pindolol with an SSRI improves early outcomes in people with depression |journal=Evid Based Ment Health |volume=7 |issue=4 |pages=107 |date=November 2004 |pmid=15504795 |doi= 10.1136/ebmh.7.4.107|url=http://ebmh.bmj.com/cgi/pmidlookup?view=long&pmid=15504795}}</ref> if the patient fails to respond to the standard therapy alone. Fluoxetine is the most commonly used standard antidepressant. The results of augmentation therapy are encouraging. It is not known whether pindolol has antidepressive activities as monotherapeutic agent. | |||
* Augmentation therapy of [[premature ejaculation]]: According to a recent study, pindolol can be effectively added to a standard anti-premature-ejaculation therapy, which usually consists of daily doses of an SSRI antidepressant such as fluoxetine or paroxetine. Augmentation of pindolol results in substantial increase of ejaculatory latency, even in those who previously did not experience in an improvement with the SSRI monotherapy.<ref>{{cite journal | last1 = Safarinejad | first1 = MR | title = Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. | journal = Journal of Clinical Psychopharmacology | volume = 28 | issue = 1 | pages = 39–44 | year = 2008 | pmid = 18204339 | doi = 10.1097/jcp.0b013e31816073a5}}</ref> | |||
==Contraindications== | |||
{{See Also|Propranolol}} | |||
Similar to propranolol with an extra contraindication for hyperthyroidism. In patients with thyrotoxicosis, possible deleterious effects from long-term use of pindolol have not been adequately appraised. Beta-blockade may mask the clinical signs of continuing hyperthyroidism or complications, and give a false impression of improvement. Therefore, abrupt withdrawal of pindolol may be followed by an exacerbation of the symptoms of hyperthyroidism, including thyroid storm.<ref>http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20%28General%20Monographs-%20V%29/VISKEN.html</ref> | |||
Pindolol has modest [[beta-adrenergic agonist]] activity and is therefore used with caution in [[angina pectoris]]. | |||
==Dosage== | |||
Usual doses are 5 mg 3 or 4 times daily or 15 to 20 mg in one single dose daily. Slow Release forms (20 mg) may be available to increase patient compliance. The maximum daily dose is 60 mg for hypertension and 40 mg for angina. Treatment should be started with low doses and slowly increased according to the clinical response. The initial and maintenance doses should be reduced in patients with severe liver disease. In some countries pindolol exists as injection concentrate for the emergency treatment of serious arrhythmias. In these cases 0.4 to 1 mg is injected i.v. under strict ECG-monitoring. Further treatment, if necessary, should then be oral. | |||
The recommendation for augmentation in depressive patients is 2.5 mg (or possibly 5 mg) three times daily. | |||
==References== | ==References== | ||
| Line 87: | Line 69: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Beta blockers]] | [[Category:Beta blockers]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 17:16, 8 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information about Pindolol, click here.
Synonyms / Brand Names: Visken
Overview
Pindolol (Visken, Betapindol, Blockin L, Blocklin L, Calvisken, Cardilate, Decreten, Durapindol, Glauco-Visken, Pectobloc, Pinbetol, Prindolol, Pynastin) is a beta blocker.
Category
Beta blockers
FDA Package Insert
Visken (pindolol) Tablet
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | How Supplied/Storage and Handling | Patient Counseling Information
Mechanism of Action
Pindolol is a nonselective beta blocker with partial beta-adrenergic receptor agonist activity. It possesses ISA (Intrinsic Sympathomimetic Activity). This means that pindolol, particularly in high doses, exerts effects like epinephrine or isoprenaline (increased pulse rate, increased blood pressure, bronchodilation), but these effects are limited. Pindolol also shows membrane stabilizing effects like quinidine, possibly accounting for its antiarrhythmic effects. It also functions as a 5-HT1A receptor weak partial agonist / antagonist (Ki=33nM[1]).
Pharmacokinetics
Pindolol is rapidly and well absorbed from the GI tract. It undergoes some first-pass-metabolization leading to an oral bioavailability of 50 to 95%. Patients with uremia may have a reduced bioavailability. Food does not alter the bioavailability, but may increase the resorption. Following an oral single dose of 20 mg peak plasma concentrations are reached within 1 to 2 hours. The effect of pindolol on pulse rate (lowering) is evident after 3 hours. Despite the rather short halflife of 3 to 4 hours, hemodynamic effects persist for 24 hours after administration. Plasma halflives are increased to 3 - 11.5 hours in patients with renal impairment, to 7 – 15 hours in elderly patients, and from 2.5 to 30 hours in patients with liver cirrhosis. Approximately 2/3 of pindolol are metabolized in the liver giving hydroxylates, which are found in the urine as gluconurides and ethereal sulfates. The remaining 1/3 of pindolol is excreted in urine in unchanged form.
Indications
- Angina pectoris and hypertension. The use of pindolol in the treatment of unstable angina may be less effective compared to beta blockers without ISA.
- In some other countries also arrhythmias and prophylaxis of acute stress reactions.
Investigational Use
- Augmentation therapy of clinical depression: Pindolol is sometimes added to a standard antidepressant therapy,[2] if the patient fails to respond to the standard therapy alone. Fluoxetine is the most commonly used standard antidepressant. The results of augmentation therapy are encouraging. It is not known whether pindolol has antidepressive activities as monotherapeutic agent.
- Augmentation therapy of premature ejaculation: According to a recent study, pindolol can be effectively added to a standard anti-premature-ejaculation therapy, which usually consists of daily doses of an SSRI antidepressant such as fluoxetine or paroxetine. Augmentation of pindolol results in substantial increase of ejaculatory latency, even in those who previously did not experience in an improvement with the SSRI monotherapy.[3]
Contraindications
Similar to propranolol with an extra contraindication for hyperthyroidism. In patients with thyrotoxicosis, possible deleterious effects from long-term use of pindolol have not been adequately appraised. Beta-blockade may mask the clinical signs of continuing hyperthyroidism or complications, and give a false impression of improvement. Therefore, abrupt withdrawal of pindolol may be followed by an exacerbation of the symptoms of hyperthyroidism, including thyroid storm.[4]
Pindolol has modest beta-adrenergic agonist activity and is therefore used with caution in angina pectoris.
Dosage
Usual doses are 5 mg 3 or 4 times daily or 15 to 20 mg in one single dose daily. Slow Release forms (20 mg) may be available to increase patient compliance. The maximum daily dose is 60 mg for hypertension and 40 mg for angina. Treatment should be started with low doses and slowly increased according to the clinical response. The initial and maintenance doses should be reduced in patients with severe liver disease. In some countries pindolol exists as injection concentrate for the emergency treatment of serious arrhythmias. In these cases 0.4 to 1 mg is injected i.v. under strict ECG-monitoring. Further treatment, if necessary, should then be oral.
The recommendation for augmentation in depressive patients is 2.5 mg (or possibly 5 mg) three times daily.
References
- ↑ "PDSP". Retrieved 12 June 2013.
- ↑ Isaac MT (November 2004). "Review: combining pindolol with an SSRI improves early outcomes in people with depression". Evid Based Ment Health. 7 (4): 107. doi:10.1136/ebmh.7.4.107. PMID 15504795.
- ↑ Safarinejad, MR (2008). "Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study". Journal of Clinical Psychopharmacology. 28 (1): 39–44. doi:10.1097/jcp.0b013e31816073a5. PMID 18204339.
- ↑ http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20%28General%20Monographs-%20V%29/VISKEN.html